Your AI-Trained Oncology Knowledge Connection!
In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.
In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.
In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.
We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.
Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.
Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.
Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.
We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.
We recently traveled to Nashville, Tennessee for a State of the Science Summit™ on Genitourinary Malignancies, which featured insights from Vanderbilt-Ingram Cancer Center faculty.
In our exclusive interview, Dr. Marshall provides his perspective on physician burnout in oncology, discusses the long-term personal and professional consequences of burnout, and shares ways to reduce oncology burnout on an individual and organizational level.
Today, we passed the mic to Petros Grivas, MD, PhD, who moderated a discussion on a multi-institutional registry that has been created to capture data from healthcare professionals on patients with cancer who have suspected or confirmed diagnoses of the novel coronavirus, COVID-19. Joining Dr. Grivas is Jeremy L. Warner, MD, MS, as well as Ali R. Khaki, MD.
Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.
We recently traveled to Summit, New Jersey for a State of the Science Summit on Lung Cancer, which featured insights from Memorial Sloan Kettering Cancer Center faculty.
In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.
We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.
Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.
We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.
In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.
We traveled to Austin, Texas, for a State of the Science Summit™ on Precision Medicine, which featured insights from the Texas Oncology faculty.
Lecia V. Sequist, MD, MPH, and Zofia Piotrowska, MD, MHS, give their input on how they approach cases that are often encountered in clinic.
We traveled to Phoenix, Arizona, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the Mayo Clinic and Benner MD Anderson Cancer Center faculty.
Omid Hamid, MD, and Grace Cherry, NP, share the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities.
We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.
Stephanie L. Graff, MD, shared the importance of personalizing care for her patients with breast cancer, how she balances her professional and personal life, using the optimal voice on social media, and her vision for the future of breast cancer treatment.
We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.
Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.
We traveled to Philadelphia, Pennsylvania, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the University of Pennsylvania faculty.
We traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer, which featured insights from the University of Chicago faculty.
Dr. Tanios Bekaii-Saab spent time discussing the path to practicing in gastrointestinal malignancies, how he navigates balancing his professional and personal life, and mottos he has lived by throughout his career and while caring for his patients.
We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.
